Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Biomarker testing sits at the center of this dementia and brain health question.
Biomarker testing has fundamentally changed how researchers identify and enroll patients in dementia and Alzheimer’s disease clinical trials. Rather than relying solely on cognitive symptoms and brain imaging, modern trials use biomarkers—measurable biological indicators—to pinpoint who is most likely to benefit from experimental treatments and to ensure study populations are truly comparable. A patient with cognitive complaints and a brain MRI might have been enrolled in a trial a decade ago, but today that same patient would first undergo cerebrospinal fluid analysis, positron emission tomography (PET) scans, or blood tests for phosphorylated tau and amyloid-beta to confirm the actual pathology driving their symptoms.
This shift has made clinical trials more scientifically rigorous but also more restrictive. Biomarkers serve as a gatekeeping mechanism that can exclude people who might have benefited from a treatment, while simultaneously ensuring that trial results reflect the true effect of a drug on a specific biological process. Understanding how these tests work and why trials require them is essential for anyone considering research participation or advocating for a family member.
Table of Contents
- What Are Biomarkers and Why Do Trials Use Them for Enrollment?
- The Practical Barriers Created by Biomarker Requirements
- How Different Biomarker Tests Shape Who Gets Enrolled
- Stratification and Risk: How Biomarkers Help Match Patients to Treatments
- The Timing Question—When Should Biomarker Testing Occur?
- Ethnic and Demographic Variations in Biomarker Interpretation
- The Future of Biomarker-Based Trial Design
- Conclusion
- Frequently Asked Questions
What Are Biomarkers and Why Do Trials Use Them for Enrollment?
Biomarkers in dementia research are objective, measurable indicators of pathological changes in the brain. The most validated biomarkers in Alzheimer’s disease include amyloid-beta accumulation, tau pathology (particularly phosphorylated tau variants), neuroinflammation markers, and neurodegeneration signs. Researchers distinguish between biomarkers of amyloid pathology (A), tau pathology (T), and neurodegeneration (N)—a framework that helps standardize how trials classify participants. Unlike cognitive tests, which depend on the participant’s effort and the clinician’s skill, biomarkers provide objective data about underlying disease mechanisms.
Trials use biomarkers for enrollment because drugs target specific pathological processes. An anti-amyloid monoclonal antibody, for instance, is only expected to slow cognitive decline in people who actually have amyloid accumulation in the brain. Enrolling patients without amyloid pathology would dilute the drug’s measured effect and might lead researchers to incorrectly conclude the treatment is ineffective when it actually works in the right population. One landmark trial showed that participants with confirmed amyloid pathology experienced a 35% slowing of cognitive decline with an anti-amyloid antibody, while historical controls without biomarker confirmation had shown much smaller treatment effects—highlighting how enrichment via biomarkers sharpens scientific signals.
The Practical Barriers Created by Biomarker Requirements
While biomarkers improve trial quality, they also create significant enrollment obstacles. The tests themselves are expensive: a tau PET scan can cost $3,000 to $5,000, a cerebrospinal fluid collection via lumbar puncture carries small but real risks including post-dural puncture headache, and blood biomarker panels, while cheaper, are still not universally available in rural areas or underserved communities. Many patients who might qualify cognitively find themselves ineligible because they cannot access baseline biomarker testing before trial enrollment, or they fear the lumbar puncture procedure despite its safety track record.
This creates an inequity problem in dementia research. Trials become skewed toward patients in urban areas near medical centers with cutting-edge imaging equipment and specialists who know how to order and interpret biomarkers. A rural patient with early cognitive decline may never even learn whether they have underlying Alzheimer’s pathology because they live six hours from the nearest PET imaging center. Furthermore, the requirement for specific biomarker cutoffs—for example, a tau PET standard uptake value ratio above 1.3—can exclude people with early pathology that hasn’t yet crossed the trial’s threshold, even though they might represent an earlier stage where intervention could be most effective.
How Different Biomarker Tests Shape Who Gets Enrolled
The specific biomarker required for a trial dramatically alters who becomes eligible. trials targeting early Alzheimer’s pathology increasingly require amyloid PET and tau PET imaging, which identifies people in the asymptomatic or mildly symptomatic stages of disease but excludes those whose cognitive changes stem from other causes like vascular disease, Lewy body pathology, or frontotemporal degeneration. In contrast, trials for Lewy body dementia might require dopamine transporter imaging (DAT scans) to confirm substantia nigra degeneration, a completely different enrollment gate. Blood-based biomarkers have democratized access in some ways while reshaping inclusion criteria in others.
A patient with cognitive complaints can now undergo a simple blood draw to measure phosphorylated tau-181 or phosphorylated tau-217, with results available in weeks rather than months. This has enabled some trials to broaden enrollment geographically since the test doesn’t require expensive imaging infrastructure. However, blood biomarkers have their own cutoff limitations: a phosphorylated tau-181 level of 25 pg/mL might separate cognitively normal individuals with preclinical pathology from those without disease, but this cutoff was derived from specific cohorts and may not apply equally across all ethnic groups or in people with other comorbidities. A 65-year-old with hypertension and prediabetes might have an elevated phosphorylated tau level stemming partly from vascular stress rather than primary Alzheimer’s pathology, yet the blood test alone cannot distinguish this nuance.
Stratification and Risk: How Biomarkers Help Match Patients to Treatments
Beyond simple inclusion and exclusion, biomarkers allow trials to stratify participants into risk or pathology subgroups, ensuring that each group receives balanced treatment. A trial might stratify by amyloid and tau positivity separately, ensuring that the placebo group and treatment group each have similar proportions of people with both pathologies. This reduces noise and makes the trial more statistically powerful. Alternatively, trials use biomarkers to predict which participants are most likely to show cognitive decline over the study period, allowing researchers to focus on the subpopulation most likely to benefit.
There is a tradeoff, however: while stratification improves internal validity, it can limit the generalizability of results. If a trial stratifies by requiring biomarker evidence of both amyloid and tau pathology—meaning participants have dual pathology—the results may not apply to patients with amyloid pathology alone, even though they might benefit. The drug was tested in a narrowly defined population, which is scientifically clean but practically restrictive. A patient whose autopsy-confirmed pathology shows amyloid but minimal tau might read headlines about a successful trial yet find their physician reluctant to prescribe the drug off-label because evidence specifically in their subgroup is limited.
The Timing Question—When Should Biomarker Testing Occur?
Biomarkers can change over time as disease progresses, raising important questions about when testing should occur relative to trial enrollment. Some trials require biomarker assessment within 6 months of enrollment, while others demand it within 4 weeks to minimize the chance that pathology status has shifted. Early-stage trials, particularly those enrolling asymptomatic or mildly symptomatic people, might use biomarkers to predict future cognitive decline—a prognostic use rather than a diagnostic one. These predictive biomarkers have higher uncertainty margins than biomarkers used to confirm current pathology.
Another critical limitation: biomarker results can vary by imaging center, scanner type, and analysis method. One PET center’s threshold for amyloid positivity might be calibrated differently than another’s, potentially leading to a participant being enrolled in one trial but excluded from another despite having the same underlying pathology. This problem is slowly being addressed through standardized imaging protocols, but it remains a real source of variability. Additionally, some participants with clear cognitive decline have negative biomarker results—they don’t fit the expected amyloid or tau signature. These cognitively impaired but biomarker-negative individuals are often excluded from modern trials, yet their exclusion means we learn little about what is causing their decline or whether they might benefit from treatments designed for amyloid or tau.
Ethnic and Demographic Variations in Biomarker Interpretation
Biomarker cutoffs were established largely in predominantly white research cohorts, and emerging evidence suggests that amyloid burden, tau accumulation patterns, and blood biomarker levels may differ across ethnic groups due to genetic variation, cardiovascular risk differences, and other factors. A Black American with a phosphorylated tau-181 level of 20 pg/mL might have substantively different disease trajectory than a white American with the same level, yet both would be assessed against the same trial threshold. Some trials now collect demographic stratification data, but few have formally re-calibrated biomarker cutoffs for diverse populations.
This gap means that current biomarker-based trials may inadvertently exclude or include participants in ways that don’t reflect their true disease status. A person from an underrepresented racial or ethnic group might be denied trial participation because their biomarker values fall just below the cutoff, not realizing that those values may have a different prognostic meaning for their group. Conversely, some might be enrolled based on biomarker cutoffs that were not validated in their demographic, potentially affecting both their care and the scientific validity of the results.
The Future of Biomarker-Based Trial Design
The future of clinical trial enrollment likely involves multimodal biomarker panels and machine learning algorithms that integrate multiple markers—amyloid, tau, neurodegeneration, inflammatory markers, and genetic risk factors—to create a more nuanced eligibility profile. Rather than a single blood test cutoff, trials may use algorithms that weigh different biomarkers differently depending on age, genetics, and other factors. This could allow researchers to enroll participants with truly comparable underlying biology while reducing the false inclusions and exclusions that single-marker approaches generate.
However, this sophistication also risks further narrowing trial populations to those with access to comprehensive biomarker testing and to researchers with expertise in interpreting complex multimodal data. The field will need to balance scientific rigor with practical accessibility if biomarker-enriched trials are to advance both scientific knowledge and patient welfare. Additionally, as our understanding of dementia heterogeneity grows, trials may shift toward smaller, more deeply phenotyped cohorts rather than large, standardized populations, fundamentally changing how research translates to clinical practice.
Conclusion
Biomarker testing has reshaped clinical trial eligibility by replacing symptom-based enrollment with objective measures of underlying pathology. This makes trials more scientifically powerful and results more interpretable, but it also creates barriers to participation and raises questions about equity, generalizability, and the experience of people whose cognitive decline doesn’t fit established biomarker patterns.
For anyone considering trial participation or supporting a family member in that decision, understanding what biomarkers a trial requires—and why—is the first step toward informed choice. As the field moves toward even more sophisticated biomarker strategies, the challenge will be maintaining scientific rigor while ensuring that trials remain accessible and that their results apply broadly to the diverse populations living with dementia. If you are interested in trial participation, starting a conversation with your neurologist or a clinical research coordinator about your biomarker status, the availability of testing in your area, and how results might affect eligibility for studies aligned with your goals can help clarify realistic options.
Frequently Asked Questions
Are all dementia trials now required to use biomarkers for enrollment?
No, but the majority of research trials for Alzheimer’s disease and related conditions now include biomarker requirements, especially larger Phase 2 and Phase 3 trials testing disease-modifying drugs. Smaller trials, quality-of-life studies, and trials testing supportive care interventions may have less stringent biomarker requirements. Always ask the trial team about specific eligibility criteria.
If I have cognitive symptoms but a negative amyloid biomarker, does that mean I don’t have Alzheimer’s disease?
Not necessarily. A negative amyloid biomarker suggests you don’t have amyloid-driven Alzheimer’s pathology, but your cognitive decline could stem from tau pathology alone, vascular disease, Lewy body pathology, or other causes. This is precisely why some patients with cognitive symptoms are not eligible for amyloid-targeted trials but might be eligible for trials targeting different pathways.
How much does biomarker testing cost, and is it covered by insurance?
Blood-based biomarker panels typically cost $500 to $1,500 and are increasingly covered by insurance if ordered by a neurologist for diagnostic purposes. PET imaging and cerebrospinal fluid testing can cost $3,000 to $8,000 per test. Insurance coverage varies widely, and trials often cover biomarker testing as part of enrollment screening.
Can I participate in a clinical trial if I live in a rural area without access to PET imaging?
Some trials are expanding the use of blood-based biomarkers specifically to increase accessibility in rural and underserved regions. Check with local research sites or the trial’s website to see whether remote or telemedicine visits, with blood draws at a local lab, might meet their requirements.
If I don’t meet a trial’s biomarker cutoff by a small amount, can I still participate?
In general, no—trial protocols have defined thresholds to ensure study integrity. However, it’s worth discussing your specific situation with the trial coordinator, as some trials have minor flexibility or upcoming studies that may have different requirements.
Why do biomarker results sometimes differ between imaging centers?
Different PET scanners, analysis software, and technician training can produce slightly different measurements of the same pathology. Standardized imaging protocols are improving consistency, but variations remain. Always ask the trial team which imaging centers are approved for biomarker assessment.
You Might Also Like
- Why Trial Participation Is Not the Same as Treatment
- Why Trial Access Is Unequal
- Can Rural Patients Join Dementia Trials?
For more, see National Institute on Aging.
